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ABSTRACT

Hammoud, Nadine M. M.S., Purdue University, December 2014. The Impact of an
Omega-3 Enriched Diet on Hyperactivity and Biochemistry in an Animal Model for
Attention-Deficit/Hyperactivity Disorder. Major Professor: John Burgess.
Attention-deficit/hyperactivity disorder (ADHD) is the most diagnosed behavioral
disorder in children. It affects around 5% of children worldwide and 11% of children in
the United States, with rates increasing. Pharmaceutical treatments, such as
amphetamines and methylphenidates, are not effective for everyone and are known to
have unwanted side effects. While the etiology of the disorder is not yet fully understood,
there are clear genetic and environmental components. Nutritional insufficiencies have
recently become a popular environmental risk factor under investigation. Essential fatty
acids (EFA), omega-3 polyunsaturated fatty acids (PUFA) in particular, are needed for
proper brain development and function. Our lab has found lower proportions of omega-3
PUFA in the phospholipids and red blood cell membranes of about 40% of the children
and adults with ADHD. Other research groups have subsequently confirmed similar
findings. It is not yet known why a subgroup of the ADHD population seem to display
EFA insufficiency, or if supplementation can reliably prevent or alleviate symptoms of
the disorder. However, multiple human and animal studies have reported a reduction in
ADHD-symptoms with omega-3 PUFA supplementation. Thus, we hypothesized that an
omega-3 PUFA enriched diet would reduce the ADHD symptom of hyperactivity,
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modulate dopamine and serotonin turnover, and increase omega-3 PUFA proportion in
plasma and brain phospholipids in the Spontaneously Hypertensive Rat (SHR) animal
model for ADHD. Additionally, we explored the relationship between oxidative stress,
EFA status, and ADHD behavior with the prediction that SHR will display greater
oxidative stress than the control strain, Wistar Kyota Rat (WKY). In order to develop a
protocol that elucidates the behavioral differences between the two rat strains, we
conducted a pilot study on various behavioral tests on the WKY and SHR while on
standard rat chow. Results from our preliminary data led us to use the open field test as a
measure of hyperactivity. In our intervention study, the omega-3 enriched diet (omega-3
diet) had no impact on measures of hyperactivity. However, our intervention successfully
increased omega-3 PUFA proportions in plasma and brain phospholipid membranes.
WKY had a higher proportion of eicosapentaenoic acid (EPA) in both plasma and brain
than SHR, and SHR had a higher proportion of docosahexaenoic acid in plasma for both
diets. Results of the liver total glutathione (GSH) analysis suggested that the omega-3
diet reduced oxidative stress, but that the SHR had lower oxidative stress than the WKY.
SHR on the omega-3 diet had a lower concentration of dopamine in the neostriatum than
SHR on the omega-6 dominant diet, and both rat strains on the omega-3 diet had lower
serotonin concentration. Consistent with the lack of impact on behavior, dopamine and
serotonin turnover were not modulated by diet. However, dopamine turnover in the SHR
was lower than that in the WKY. In summary, our dietary intervention did not impact
behavior, which was consistent with the lack of impact on neurotransmission, despite the
alteration in phospholipid proportions. Future studies should focus on determining the
most effective dose, EPA/DHA ratio, and time period for an omega-3 PUFA intervention.
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CHAPTER 1. INTRODUCTION

1.1

Objectives and Organization

The overall goal was to examine the possible impact of an omega-3 enriched diet
on Attention-deficit/hyperactivity disorder (ADHD) behavior, particularly as it relates to
neurotransmission, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)
proportion in plasma and brain and oxidative stress. The specific hypothesis that was
tested is that a higher plasma and brain phospholipid proportion of EPA and DHA,
obtained from diet, can reduce hyperactivity, improve dopamine and serotonin utilization,
and reduce oxidative stress.
The specific objectives were to:
1. Evaluate the behavioral effects of an omega-3 enriched diet on hyperactivity in
comparison to an omega-6 dominant diet in an animal model.
2. Examine biochemical markers in the animal brain, plasma, and liver to determine
the relationship between behavior, neurotransmission, oxidative stress, and brain
and plasma phospholipid composition, along with any impact of diet or strain.
This thesis covers topics regarding the relationship between ADHD, essential fatty
acids (EFAs), and oxidative stress in 4 chapters. Chapter 1 is a literature review that
covers general background ADHD information, the relationship between essential fatty
acids and brain function and behavior, and studies reporting the impact of omega-3
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supplementation on ADHD behavior. It will also include a review of omega-3
polyunsaturated essential fatty acids, oxidative stress, and the history of the validated
animal model for ADHD. Chapter 2 is a supplemental chapter detailing a pilot study used
to validate behavioral differences between the SHR and WKY, and behavioral tests.
Chapter 3 describes the design and results of our animal study on the impact of an
omega-3 enriched diet on behavior, neurotransmission, essential fatty acid proportion,
and oxidative stress. Chapter 4 will conclude with a summary of the work, conclusions,
and future directions.

1.2

Attention-Deficit/Hyperactivity Disorder

Attention-deficit/hyperactivity disorder is the most commonly diagnosed
behavioral disorder in children. Diagnosis is based off of criteria set by the Diagnostic
and Statistical Manual of Mental Disorders (5th edition) (DSM-V), which is a
classification and diagnostic tool used by psychologists and researchers. According to the
DSM-V, ADHD is characterized by symptoms of inattention, hyperactivity, and
impulsiveness. Manifestations of these symptoms include: frequent daydreaming,
interrupting others, inability to remain seated, and/or not listening when spoken to.
Children under the age of 17 must exhibit at least 6 of the 9 inattentive and/or
hyperactive and impulsive symptoms, while adults need only to display 5 or more
symptoms1. This is a change from the previous criteria reported in the DSM-IV, in order
to reflect the reduction of symptoms that commonly occurs with age2. Furthermore, there
must be clear evidence that the symptoms interfere with, or reduce, the quality of social,
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academic, or occupational functioning. Finally, more accountable causes of the
symptoms must be ruled out before reaching a diagnosis.
ADHD is divided into three subtypes: Combined presentation, Predominantly
Inattentive presentation, and Predominantly Hyperactive-Impulsive presentation. In
Combined presentation, the individual displays symptoms of inattention, hyperactivity,
and impulsiveness. In the Inattentive or Hyperactive-Impulsive presentation, the
individual primarily displays symptoms of inattention or both hyperactivity and
impulsiveness. The clinician must also specify whether the client’s ADHD is mild,
moderate, or severe, which is determined by the number of symptoms presented1.
ADHD is commonly co-morbid with other psychological disorders. In reviews of
ADHD diagnosis, symptoms, and treatment, 25-75% of teens with ADHD are reported to
meet the criteria for oppositional defiant or conduct disorder. Depression and anxiety are
two other common co-morbid disorders with 48% and 36% receiving the additional
diagnosis, respectively3,4. ADHD is also commonly co-morbid with other disorders such
as tic disorders, Obsessive Compulsive Disorder, and sleep difficulties4.

1.2.1

Demographics

As previously stated, ADHD is the most common behavioral disorder in children.
It affects around 5% of children (ages 4-17) worldwide, and up to 11% of children in the
United States (US)5. The percentage of children with an ADHD diagnosis has been
increasing yearly, with rates at 7.8% in 2003, 9.5% in 2007 and rising to 11% in 20116.
This is an average increase of 5%/year from 2003-20117. Males are three times more

4
likely to have an ADHD diagnosis than females. ADHD diagnosis also varies by state,
with the highest rates in the Midwest and some states on the East Coast6.

1.2.2

Neurobiology

There are multiple theories regarding the physiology of ADHD, and dopamine
(DA) neurotransmission abnormalities are heavily implicated in most of them. Dopamine
is a catecholamine neurotransmitter, a chemical messenger in the brain, which plays an
essential role in attention, motivation, learning, and memory. Major dopamine pathways
run through the striatum and the frontal cortex regions of the brain – areas implicated in
ADHD. Dopamine is primarily produced in the substantia nigra or the ventral tegmental
area (VTA), both of which are located in the midbrain (Figure 1). Consequently, these
areas are often analyzed when researching dopamine. Projections from these neurons go
to the striatum, the nucleus accumbens, and the prefrontal cortex in addition to other
areas of the brain. Dopamine exerts an effect by binding to cell-surface receptors.
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Figure 1: Dopaminergic Pathways
There are 5 types of dopamine receptors (D1-D5), which all function as G-protein
receptors. However, D2 and D4 are currently the main dopamine receptors of interest in
ADHD research8,9. A simplified model of how dopamine is controlled at the synaptic
level could be described by: (1) pre-synaptic cell firing releases dopamine into the
synaptic cleft; (2) dopamine then reversibly binds to dopamine receptors on the post
synaptic cell; (3) dopamine is either reabsorbed by dopamine transporters and degraded
into homovanillic acid (HVA) or is recycled for further use (see Figure 2)9. Of note,
dopamine is a precursor to norepinephrine, which is also crucial for short-term memory
and attention.
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Figure 2: Dopamine Metabolism
Among the multiple theories that have been proposed for the cause of ADHD
behavior, it is generally agreed upon that the cause involves disturbances in the
dopaminergic pathway. Some points of contingency stem from whether these
disturbances result in a hyperdopaminergic state, hypodopaminergic state, or if there are
alternative consequences. Currently, one of the most supported theories is that those with
ADHD have a dopamine deficit, meaning they have low dopamine production or
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response for reasons not fully understood9. Multiple neurobiological studies have been
conducted to decipher the cause of the proposed dopamine deficit. Castellanos et al.9
investigated whether there are size abnormalities in dopamine-modulated areas of the
brain. The researchers measured brain volumes of 152 children and adolescents with
ADHD and compared the sizes to healthy controls using magnetic resonance images. The
researchers found that brain regions with high dopamine receptors were significantly
smaller in the ADHD group than the control. Their longitudinal growth curves suggested
that this decrease in volume occurs early in development, as fundamental developmental
processes appeared to be healthy10. Another area to investigate is dopamine function.
Volkow et al.11 measured dopamine receptor availability and dopamine release in ADHD
adults using positron emission tomography. The researchers found that dopamine
receptor availability in the left caudate was significantly lower in subjects with ADHD (p
< 0.04), and showed a trend in the right caudate (p < 0.07). In addition to lower dopamine
receptor availability, the ADHD subjects were reported to have lower dopamine release
as well11.
In congruence with the hypodopaminergic theory, there is also evidence that
patients with ADHD have low dopamine response. Wigal et al.12 tested ten untreated
children with ADHD versus eight age-matched controls by having them undergo two
separate exercise sessions. Exercise is known to elicit a dopamine and norepinephrine
response and peripheral nervous system activity is correlated with brain activity. They
found that the children with ADHD had significantly lower plasma norepinephrine at alltime points and significantly lower dopamine at the peak of the exercise compared to
controls. However, it is yet to be determined whether the lack of dopamine response is
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due to a systematic dopamine deficit or to less stimulation of the adrenals in response to
exercise12. Nonetheless, the results provide further support that ADHD symptoms may be
a result of a hypodopaminergic state.

1.2.3

Treatment

ADHD is normally treated with the use of amphetamines (ex. Adderall) or
methylphenidates (ex. Ritalin). Both treatments either indirectly or directly increase the
amount of dopamine in the synapse. Amphetamines cause an increase in dopamine
release. Methylphenidates, on the other hand, block dopamine reabsorption by blocking
the dopamine active transporter (DAT). Blocking reabsorption increases the amount of
dopamine in the synapse, which allows dopamine to repeatedly bind to dopamine
receptors13. However, stimulants may act in other additional ways that help reduce
hyperactivity. While stimulant medication can alleviate symptoms, it is only effective for
around 70% of adolescents4. Common side effects include upset stomach, headache,
decreased sleep, and decreased appetite. Recently, non-stimulant atomoxetine has been
approved for ADHD treatment. Atomoxetine is a selective inhibitor of the presynaptic
noradrenaline transporter with low affinity for serotonin (5-HT) and dopamine transporter
receptors14. Preliminary evidence suggests that atomoxetine may be beneficial for ADHD
that is co-morbid with anxiety and depression, two common co-morbid disorders15.

1.2.4

Etiology

The etiology of ADHD is not yet known, but there are clear genetic and
environmental components. Based on many twin and adoption studies, the estimated
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heritability of ADHD is almost 80% and this rate has not changed since 197316. Parents
of adopted children with ADHD are less likely to have the disorder than biologically
related relatives17. Thus, genetics seems to play an important role in initiating ADHD.
There are a few genetic studies that have identified genes with polymorphisms that
are associated with ADHD18. The most frequently implicated genetic factors are the
dopamine D4 receptor (DRD4) and the dopamine transporter gene (DAT1). Both these
genes play important roles in the dopaminergic system. DRD4 has been frequently
analyzed due to its prevalence in the frontal-subcortical networks. Dopamine, along with
norepinephrine, are potent agonists for this receptor19. Many researchers have assayed a
tandem repeat polymorphism in exon III of DRD4 because it has been shown that the 7repeat allele variant results in a low response to dopamine. In fact, a significant
association between the 7-repeat allele and ADHD in both case-control and family
studies has been reported20,21. However, other studies found no overall association of any
allele with ADHD22. Tyrosine hydroxylase, which plays a role in DA synthesis by
catalyzing the conversion of tyrosine to dihydroxy-phenylalanine, was also investigated
for its role in ADHD. However, studies have shown no association between
polymorphisms in the TH gene and ADHD23,24,25,26. There are many studies investigating
abnormalities in the dopamine transporter gene as a potential instigator of ADHD. DAT
is responsible for the reuptake DA, a preliminary step to its degradation. A polymorphism
consisting of an allele containing a 10-repeat allele of a 40-base pair variable number of
tandem repeats (VNTR) located at the 3’ untranslated, non-coding end has been primarily
investigated. The association of ADHD with this polymorphism was first proposed by
Cook et al.27, who conducted a study including 119 children with ADHD and found an
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association between this polymorphism and response to treatment. This has later been
confirmed by multiple other studies27,28. Furthermore, Dougherty et al.29 measured striatal
DA transporter activity and found that activity was elevated by 70% in ADHD adults.
Higher DA transporter activity could result in higher dopamine degradation. On the other
hand, the results of studies assessing DAT density in ADHD individuals have not been
consistent30. While there is some promising evidence supporting genetic factors, no
single gene polymorphism has enough support to be considered the sole cause of ADHD.
Thus environmental factors are also researched.

1.3

Environmental Risk Factors and ADHD

Environmental factors have become an increasingly popular focus in ADHD
research. When assessing ADHD risk, environment factors are commonly classified as
prenatal, perinatal, and postnatal31. Multiple meta-analyses and reviews have assessed
common environmental factors for positive correlation with ADHD risk. The risk factors
that will be discussed in this review include: cigarette and alcohol exposure, lead
exposure, and nutritional insufficiencies.

1.3.1

Maternal Smoking

Maternal smoking during pregnancy is significantly associated with increased
ADHD risk in the offspring32. Braun et al.33 obtained data from the National Health and
Nutrition Examination Survey from 1999-2002. Among 4,704 children aged 4-15 years
old, 4.2% had ADHD and took stimulant medication. Using multivariable analysis, they
found that prenatal tobacco exposure [odds ratio (OR) = 2.5;95% confidence interval (CI),

11
1.2-5.2] was significantly associated with ADHD, however, postnatal maternal smoking
was not. The researchers suggest that prenatal exposure to tobacco could account for up
to 270,000 excess cases of ADHD 33.

1.3.2

Prenatal Alcohol Exposure

The risk of prenatal exposure to alcohol seems to be dependent on severity and
duration of alcohol consumption, thus the research has not been uniform31. However, in a
retrospective, case-control study conducted by Mick et al.34 it was reported that those
exposed to alcohol in utero were 2.5 times more likely to have ADHD, independent of
nicotine exposure. The researchers concluded that alcohol is a risk factor of ADHD. In
addition, Knopik et al.35 reported that offspring of twins with a history of alcohol abuse
were significantly more likely to develop ADHD than offspring of nonalcoholic controls.

1.3.3

Lead Exposure

In addition to evaluating maternal smoking as a risk factor, Braun et al.33
investigated the risk of lead exposure. Using the same data obtained from the National
Health and Nutrition Examination Survey, the researchers found higher blood lead
concentrations in mothers that have children with ADHD, which could account for
290,000 excess cases of ADHD in the US. This number is equal to the excess number
resulting from tobacco exposure. Studies involving lead screening of children with
ADHD report positive correlations between mean blood lead level and ADHD36. Other
studies report variable results, but enough evidence supports that prenatal exposure to
lead is a risk factor31.
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1.3.4

Nutritional Insufficiencies

Low nutrient status has been associated with a number of disorders. For example,
lack of vitamin C can cause the rare disease scurvy, while vitamin D deficiency can lead
to a disorder of the bone, known as rickets. Nutritional insufficiencies may also impact
behavioral disorders, and have been investigated within ADHD research.
A relatively new risk factor associated with ADHD is vitamin D insufficiency.
The US Endocrine Society characterizes vitamin D deficiency as vitamin D levels less
than 20ng/ml, and insufficiency as vitamin D between 21-29ng/mol. Low vitamin D is a
major health concern that occurs in both low sunshine and abundant sunshine areas37. Not
only can insufficiency result from low sun exposure, but also from poor vitamin D status
during pregnancy37,38. Vitamin D is implicated as an essential component of normal brain
development as it enhances neuroprotection and modulates anti-inflammatory
mechanisms39,40. Recently, vitamin D insufficiency has been investigated for its impact
on ADHD risk. Bener et al.41 measured serum levels of vitamin D in 1331 children
displaying symptoms of ADHD or healthy controls. The researchers found that vitamin D
insufficiency was significantly greater in the children with ADHD and that these children
were more likely to have severe vitamin D deficiency41. This is one of the first
investigations into the correlation between vitamin D insufficiency and ADHD and it is a
risk factor that should be investigated further42.
Essential fatty acid insufficiency is another nutritional factor that is currently
being researched. Essential fatty acids are so named because they cannot be synthesized
in the body, and thus need to be consumed in the diet. There are two polyunsaturated
fatty acid types of interest: omega-3 polyunsaturated fatty acids (PUFAs) and omega-6
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polyunsaturated fatty acids. Inadequate intake, or excessive breakdown and excretion,
could result in a number of abnormal symptoms manifesting in the hair and skin, or
excessive thirst and urination43. Omega-3 PUFAs eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA) have been a popular topic in ADHD research due to their
known role in brain development and behavior. A study conducted in our lab on children
with ADHD and age-matched controls, identified a subgroup of children with ADHD
displaying symptoms of EFA deficiency and presenting with low proportions of omega-3
and omega-6 fatty acids in the blood44. In fact, about 40% of subjects had significantly
lower plasma omega-3 and omega-6 PUFAs than both healthy controls and those with
ADHD not displaying EFA symptoms. Chen et al.45 investigated dietary intake and blood
phospholipid levels in children with ADHD and also found that those with ADHD had
significantly lower levels of arachidonic acid (AA), an omega-6 fatty acid, and DHA,
despite similar diets to controls. Another study reported a similar finding46. Interestingly,
a recent meta-analysis on the correlation between common environmental risk factors and
ADHD reported a significant correlation between babies that were formula fed and those
that developed ADHD47. According to the authors, this finding was consistent with
previous studies and the results may be due to the greater amounts of essential fatty acids
found in breast milk. Up until 2001, commercial formula did not contain omega-3 fatty
acids48. The next section will discuss essential fatty acid biology, intake, and their
relationship with brain development and behavior in detail.
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1.4
1.4.1

Essential Fatty Acids and Brain

Essential Fatty Acid Background and Synthesis

Essential fatty acids are fatty acids that are required for biological processes but
need to be ingested from the diet. Alpha-linolenic acid (ALA) and linoleic acid (LA) are
two fatty acids that are known to be essential for humans. They are also the precursors to
omega-3 and omega-6 long-chain polyunsaturated fatty acids. The two main families of
EFAs are the omega-6 family and the omega-3 family and they are named based on the
location of the first double bond closest to the terminal (omega) end of the fatty acid
(Figure 3).

Figure 3: Omega-6 and Omega-3 Fatty Acids

Both ALA and LA contain 18-carbon long fatty acid tails. Through a series of
desaturation and elongation enzymatic steps, arachidonic acid (AA) or EPA and DHA are
synthesized, respectively. The two families share the same enzymes as illustrated in their
synthesis pathway diagram (Figure 4).
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Figure 4: Essential Fatty Acid Metabolism

1.4.2

Essential Fatty Acids in the Western Diet

Omega-3 PUFAs are very low in the typical Western Diet. On average, the ratio of
omega-6 EFAs to omega-3 EFAs is 15:149. Most omega-6 EFAs come from meat such as
red meat and poultry, which are two common foods in the western diet. They are also
found in corn and soy. On the other hand, omega-3 PUFAs are primarily found in fatty
fish such as salmon and sardines. ALA is found in flax seed and chia seeds, but the
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conversion to EPA and DHA is small49,50. An international board of lipid experts
recommended a ratio of 2:1 as most ideal51, but 4:1 is also recommended and more
attainable52,53. The acceptable intake of omega-3 EFAs is 1.6g/day for men and 1.1g/day
for women. The FDA advises that 3g/day of EPA + DHA can be ingested safely, with up
to all 2g from supplements54.

1.4.3

Essential Fatty Acid Status

Essential fatty acid status is determined by the quantity of EFAs and their products in
cells and tissues, and is usually measured via plasma analysis. Status is impacted by
dietary intake, metabolism, absorption, and degradation. Deficiency can be caused by one
of two ways: primary deficiency or secondary deficiency. Primary deficiency results from
inadequate dietary intake while secondary deficiency is the result of something internal,
such as competition for the metabolic enzymes, or an increased degradation rate. One
such factor than can increase PUFA degradation rate is oxidation from exposure to free
radicals. An accumulation of free radicals can cause macromolecule damage. When the
damage is sufficient to destroy cells and tissue, the occurrence is referred to as oxidative
stress. Oxidative stress will be discussed in more detail in a later section. Insufficiency of
one type of fatty acid can also occur when the intake of one family of fatty acid
dominates the other, as the same enzymes are used for both the omega-6 and omega-3
PUFA synthesis pathway (i.e. too much omega-6 intake could result in lower omega-3
PUFA synthesis). Furthermore, long chain PUFA synthesis is not 100%. For the omega-3
family, conversion from ALA to EPA and DHA is as low as 5-15%55,56.
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1.4.4

Brain Fatty Acid Composition

The brain is one of the fattiest organs in the body, second only to adipose tissue.
Thus, lipids are crucial for brain development and function57. Almost 66% of the brain’s
weight is due to phospholipids, 35% of which are omega-3 PUFAs. Of all the fat in the
brain, DHA makes up 10-20% and is the highest omega-3 found in the brain57. The most
dramatic brain development occurs prenatally and during the first few years of life.
Consequently, this is when adequate availability of EPA and DHA is most important.
DHA delivery to the central nervous system is most efficient during times of
synaptogenesis, which occurs most rapidly during early brain development58. Many
studies confirm that DHA is essential for optimal brain development and function59,60.
Studies conducted by Jumpsen et al.52,53 demonstrated that a ratio of 4:1 was optimal for
frontal cortex, hippocampus, and cerebellum development in growing rats. The
researchers reported that even a small change in the ratio impaired the rate of
development52,53. Furthermore, a reduced amount of DHA is compensated by an
increased amount of docosapentaenoic acid (DPA) (22:5n-6), which reduces membrane
fluidity61.

1.4.5

Oxidative Stress and Essential Fatty Acids

Fatty acids, especially those with multiple double bonds, are prone oxidation in
elevated states of oxidative stress. Oxidative stress is the imbalance of the biological
system's antioxidant defense and the manifestation of reactive oxygen species. A
disturbance in the normal redox state in cells can result in the production of peroxides or
free radicals, which can damage the DNA, carbohydrates, lipids, and proteins62. Free
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radicals are species that contain one or more unpaired electrons. Normal oxidative
metabolism results in a constant stream of oxygen derived free radicals, which are more
reactive than ground state oxygen and are thus named reactive oxygen species (ROS).
ROS can include radicals (i.e. hydroxyl radical) and non-radicals that easily degrade to
radicals (i.e. hydrogen peroxide), while the antioxidant defense system includes both
dietary and endogenously produced antioxidants such as carotenoids, tocopherols, and
thiols62.
The upregulation of antioxidant genes is one of the major mechanisms by which
cells protect themselves against oxidative stress63. Intracellular thiol groups act as
antioxidants by scavenging free radicals through enzymatic reactions62. Reduced
glutathione (GSH) is one of the most abundant and important intracellular thiols in cells 63.
Therefore cells tightly regulate the synthesis, export, and utilization of GSH. GSH elicits
its antioxidant effect by removing potentially toxic electrophiles and metals, which
protects cells from toxic oxygen products64. GSH also exhibits control in membrane
transport65. In fact, it is able to protect biological membranes against lipid peroxidation as
it prevents damage in a lipid environment62. However, its ability to protect membranes is
enzymatically mediated, and therefore dependent on, vitamin E.
Vitamin E, which encompasses a small group of tocopherols, is a major lipidsoluble antioxidant. It is primarily responsible for protecting biological membranes by
protecting membrane PUFAs from lipid peroxidation. The amount of vitamin E in
membranes often indicates the susceptibility of low-density lipoproteins, whole organs,
or microsomal membranes to oxidative damage62,66,67. Tocopherols scavenge peroxyl
radicals without reacting in chain-propagating steps, thereby protecting lipids.
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1.4.6

Essential Fatty Acids and Neural Function

As discussed previously, ADHD symptoms are thought to result from
disturbances in the dopaminergic system. Therefore, the areas of neural function that will
be discussed in this review are either directly or non-directly related to neurotransmission:
membrane fluidity, neurotransmitter activity, and neuron health.

1.4.6.1 Membrane Fluidity
Omega-3 PUFAs are thought to influence neural function in a variety of ways.
One of the most known ways is by increasing membrane fluidity. The membrane fluidity
index is primarily influenced by the percentage and composition of membrane PUFA and
membrane cholesterol content. Neuronal membranes are made up of a phospholipid
bilayer, which incorporates phospholipids from fatty acids in the diet. Saturated fatty
acids have a hydrocarbon tail with the maximum amount of hydrogen atoms possible. An
unsaturated fatty acid has a hydrocarbon tail with one or more carbon-carbon double
bonds instead of hydrogen. These double bonds cause kinks in the tail, which contribute
to membrane fluidity. Therefore, higher PUFA content results in a more fluid membrane.
On the other hand, cholesterol is needed to maintain rigidity despite high temperatures.
Interestingly, omega-3 fatty acids can actually displace cholesterol in the membrane and
thereby reduce its amount, while omega-6 fatty acids only redistribute membrane
cholesterol68. A number of research studies have shown that changing the level of EFAs
in the diet will affect the fatty acid profile in the neuronal membrane, therefore these
changes can be induced via dietary intervention69.
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Maintaining proper membrane fluidity is important for healthy neural processes.
A rigid membrane, or low membrane fluidity index, will affect receptor function, ion
channel activity, and neurotransmitter release such as dopamine68. When nerve cell
membranes are fluid, neurotransmitter receptors are better able to recognize and bind the
appropriate neurotransmitters. Since dopamine is a neurotransmitter that is heavily
implicated in ADHD behavior, improving membrane fluidity could alleviate symptoms.
Oxidative stress can also increase cholesterol levels in the brain, thereby
decreasing membrane fluidity and affecting neurotransmission70–72. In young rats,
oxidative stress was found to raise levels of brain cholesterol to that of aged rats70. The
increase of free radicals in states of heightened oxidative stress can decrease membrane
fluidity as well73,74. Some researchers have successfully corrected the harmful impact of
oxidative stress on membranes using PUFA supplementation75–78. Treatment with omega3 PUFA can also restore a long-lasting increase in synaptic efficacy following stimulation
of afferent fibers in aged rats.

1.4.6.2 Neurotransmission
Na+, K+-ATPase couples ATP hydrolysis for the active transport of 3 Na+ ions out
of the cell in exchange for 2 K+ ions into the cell. This process is integral in
neurotransmission and signaling79. Na+, K+-ATPase activity allows for rapid
repolarization of the neuron, an action needed for repetitive firing. Na+ and K+ exchange,
mediated by Na+, K+-ATPase, plays an active role in normal action potential conduction80.
Bourre et al.81 investigated the impact of an alpha-linolenic acid deficient diet on Na+,
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K+-ATPase activity in nerve endings. The researchers fed Wistar rats an ALA-deficient
diet (1.8% sunflower oil) or an ALA-adequate diet (1.9% soybean oil) for two
generations. The third generation males were used for behavioral experiments and
physiological analysis. The deficient diet successfully resulted in reduced amounts of
DHA, and increased amounts of DPA, in brain cells and organelles compared to control.
The researchers found that the nerve terminal Na+, K+-ATPase activity in rats fed the
ALA-deficient diet was reduced to 60% of the control group. In addition, those rats on
the deficient diet performed significantly worse on the shuttle box test for learning
capacity.
Dopamine and serotonin (5-HT) are implicated in many neurological disorders82.
In a study conducted by Delion et al.83 rats were fed an ALA-deficient diet over several
generations and the dopaminergic and serotoninergic systems were analyzed in the
frontal cortex, striatum, and cerebellum. The rats on the deficient diet had a 40-75%
lower level of frontal cortex endogenous dopamine. There was also an 18-46% increase
in serotonin 5-HT2 receptor density but without a change in endogenous serotonin levels.
The increase in 5-HT2 receptor density could be due to the decrease in D2 dopaminergic
receptor density which also occurred, as the two are thought to be interlinked83. Many
other studies have shown this effect of PUFA deficiency on dopamine and serotonin84. In
a study where piglets were fed an AA and DHA-deficient diet, dopamine and serotonin
concentration decreased in the frontal cortex85. Similar studies feeding rats an n-3 PUFAdeficient diet also reported a reduction in the dopaminergic vesicle pool and inadequate
storage of newly synthesized dopamine86,87. On the other hand, a study on rats given fish
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oil reported a 40% increase in dopamine concentrations in the frontal cortex and greater
binding to D2 receptors84.

1.4.6.3 Neurons
It is widely accepted that DHA plays a crucial role in brain development,
especially during periods of dramatic growth. Cao et al.88 demonstrates this fact by
testing the effect of DHA on neurite outgrowth and viability in growing cortical
neurons88. The researchers prepared cortical neurons from fetal Sprague-Dawley rat pups.
Cells were divided into DHA-treated or control groups. Different concentrations of DHA
were added to the neurobasal medium after plating. The researchers found that the DHAtreated group had significantly more neurite outgrowth and accelerated neurite elongation
than controls88. Interestingly, only a narrow concentration range of DHA had a desired
effect on neurite growth while high concentrations were actually neurotoxic to the
cortical cells. This is in agreement with other studies that report that high-dose DHA
supplementation can lead to higher peroxidation and oxidative stress, but these side
effects can be reduced with antioxidant vitamin E intake89–91. These findings support that
there may be an optimal intake of DHA to receive the best results.

1.4.7

Impact of an Essential Fatty Acid Deficit on Learning and Behavior

Several studies have shown that omega-3 PUFA deficiency can lead to functional
and learning deficits, similar to ADHD-associated problems. Rats on an ALA-deficient
diet exhibited 187% higher locomotor activity in a novel environment than control rats
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over the course of 2 hours92. Of note, this increase in activity was seen after 15 minutes
until the end of the testing period. The diet was successful in decreasing brain DHA by
80%, which was accompanied by a 575% increase in brain DPA. The alterations in
locomotor activity observed are also consistent for the potential role that omega-3 PUFA,
such as low DHA, can play in the development of ADHD. The researchers also had a
remedial diet group where rats that were previously deficient were supplemented with
DHA at weaning, a growth period that is developmentally similar to a full-term infant93.
The supplementation, however, did not have an effect on locomotor activity92.
Omega-3 PUFA deficiency has been shown to have a detrimental impact on
learning ability in multiple studies. Mice fed an ALA-deficient or ALA-adequate diet for
multiple generations demonstrated significantly decreased spatial learning and memory in
comparison to controls94,95. In one such study, previously deficient 3rd generation mice
were supplemented with omega-3 PUFA from egg yolk or pig brain for two months prior
to testing in an elevated plus maze. The supplemented mice performed just as well as the
control mice, and all groups performed better than the ALA-deficient group95, further
demonstrating that omega-3 PUFA supplementation can, in fact, reverse the negative
effects of omega-3 PUFA deficiency.

1.5

Essential Fatty Acid Intervention Studies
1.5.1

Human Intervention Studies

Several human omega-3 intervention studies have investigated the potential for
omega-3 supplements to alleviate ADHD symptoms. A meta-analysis reviewing 10 trials
involving 669 children total concluded that omega-3 supplementation was modestly
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effective in alleviating ADHD symptoms96. Bloch and Qawasmi96 also note that
supplementation with high EPA was most effective, and that while the impact is only
moderate in comparison to standard pharmaceutical treatments, it is often preferred due
to the benign nature of omega-3 supplements96. Milte et al.97 conducted a recent study
with the aim to evaluate whether a supplement with high DHA or high EPA is more
effective in treating ADHD. The 12-month randomized controlled three-way crossover
trial was conducted in children aged 6 to 13. Children were given one of three treatment
conditions: EPA-DHA-LA, DHA-LA-EPA, or LA-EPA-DHA. Each supplement was
taken for 4 months, with the omega-6 linoleic acid (LA) used for comparison. No
washout period was included because erythrocyte PUFA levels are thought to return to
baseline after 16 weeks98. Mean changes in erythrocyte fatty acids reflected what was
expected with each treatment, with EPA and DHA increasing the most after the EPA or
DHA treatment, respectively. However, mean EPA and DHA did not return completely
to baseline after LA, hinting that the washout period was not fully effective. While
conclusion statements could not be made in regards to which treatment was best (as the
washout failed), behavioral changes were compared to change in erythrocyte PUFAs. An
improvement in literacy, attention, and behavior was associated with within-subject
changes in erythrocyte PUFA. Increases in EPA, DHA, and total omega-3 PUFA and
decreases in the omega-6:omega-3 ratio had the most consistent correlations. Subscales
of parent-rated behavior and hyperactivity was also improved with high erythrocyte
omega-3 PUFA99. In a separate study, Vaisman et al.100 investigated whether omega-3
fatty acids esterified to phospholipids or triglycerides are most effective for EPA and
DHA delivery and ADHD treatment. Children were given a daily aliquot of a relatively
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low amount of EPA and DHA (153mg EPA, 95mg DHA) compared to most intervention
trials. The omega-3 PUFAs were either esterified to phospholipids or delivered via fish
oil (naturally esterified to triglyercides). Of note, the authors emulsified the fatty acids
into a chocolate spread, which may improve child adherence to the supplement regimen.
Interestingly, the EPA and DHA esterified to phospholipids resulted in the greatest
increase in plasma EPA and DHA levels. Furthermore, this increase was correlated with
the greatest improvement in behavior scores. The fish oil also increased plasma EPA and
DHA levels but the impact on behavior, though not significantly different from the
impact in the phospholipid group, was not significantly improved from placebo100. These
studies raise the question of not simply what kind of omega-3 fatty acids to supplement
with, but what kind of delivery method to use.
When reviewing all the studies investigating the impact of an omega-3
supplement on ADHD behavior, the results are not conclusive. Just as there are studies
reporting an effect, there are also studies reporting none101–103. This could be because the
intervention may best impact a subgroup of those with ADHD, most likely the same
subgroup that demonstrate omega-3 insufficiency. This is a conclusion that Belanger et al.
reported104. In their study comparing the effect of an omega-3 supplement versus an
omega-6 supplement (control) on children with ADHD, only a subgroup of the children
(30.7%) saw significant improvement in their attention. More studies are needed to
specifically evaluate treatment intervention on those displaying EFA deficiency
symptoms.
Due to the inconsistent results from human studies, and the recent validation of a
rat model for ADHD, animal studies are a relatively recent and valuable addition to
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ADHD research. By utilizing an animal model, researchers can control for the placebo
effect, perform more invasive analysis, and maintain a controlled environment. Research
from animal studies may help determine how effective an omega-3 intervention is and
pinpoint which physiological processes are being affected.

1.5.2

Animal Models and Animal Behavioral Tests for ADHD

An ideal animal model for behavioral disorders should have similar biochemistry,
etiology, symptoms, and effective treatments as the disorder in humans105. Animal
models are often advantageous over human models in that they allow for easier
controlled environments, in-depth physiological analysis, and low risk of “placebo effect”.
As ADHD diagnosis is currently only behaviorally based, the validation of an ADHD
animal model is based primarily on behavior105. Therefore, a validated animal model for
ADHD should conform to construct validity, predictive validity, and face validity.
Construct validity confirms that the animal model conforms to a theoretical rational.
Predictive validity confirms that the animal model correlates to ADHD in humans in
regards to behavior and neurological functions, while face validity means the animal
model mimics the fundamental behavioral symptoms of ADHD. Currently the
Spontaneously Hypertensive Rat (SHR/NCrl) from Charles River, Germany (Rat
Genome Database 2008) is the most validated animal model for ADHD research106.
While the best control strain is the Wistar Kyoto Rat (WKY/NHsd) from Harlan, UK.
Many studies have established face validity in the SHR. Both children with
ADHD vs control and SHR vs control have been tested on a multiple fixedinterval/extinction schedule of reinforcement107–111. A multiple schedule is defined as two
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or more schedule components alternating in the presence of different stimulus. A fixedinterval component is used to measure reactivity to reinforcers and impulsiveness, while
the extinction component measures sustained attention and sensitivity to change105. These
tests can be used to measure attention and impulsiveness. The ADHD symptom of
impulsiveness can be seen as brief, short sequences of activity and rapid changes. It is
also marked by the inability to wait, such as blurting out answers or choosing short-term
rewards over bigger, long-term ones. These bursts of activity and rapid changes are
typical in the SHR. Motor impulsiveness can be tested using the multiple fixedinterval/extinction schedule discussed above with impulsiveness measured as bursts of
responses with short inter-response times. In behavioral tests with children with ADHD,
this type of behavior is seen towards the end of testing.
Sagvolden et al.105 have conducted numerous studies in validating the SHR as a
model for ADHD. One of the earlier studies compared SHR/NCrl and WKY/NHsd
among other rat strains on their behavior when trained to respond to cue lights in a dual
lever operant chamber. The rats were trained to press a lever once the light turned on over
it and were rewarded with water. The rats were trained for weeks until ready for their
final schedule, which was used for behavioral analysis. Sustained attention was measured
as percent correct lever responses. Impulsiveness was determined by number of short
inter-response times (<0.67s) and general activity was expressed as total number of lever
presses.
The researchers reported that the male SHR/NCrl rats had significantly poorer
sustained attention compared to the WKY/NHsd and also greater general activity based
on lever presses. The SHR/NCrl was moderately more impulsive than the other groups,
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and more often responded to a previous lever press with a following lever press within
0.67s despite no reinforcement for this extra press. However, while there was a trend,
there was no significant difference between groups in terms of impulsiveness. On the
other hand, in another study by Sagvolden et al.112 impulsiveness was found to be
significantly higher for SHR than WKY.
An open field maze can also be used to measure hyperactivity by measuring
general locomotion. In this behavioral test, an animal is placed on one spot in a square
open field with four walls. The floor is normally divided into squares and locomotion is
measured as number of boxes crossed or via video recording and computer analysis. In
addition, number of center box entries and number of rearings can also be measured.
Normal rats are expected to stick to the perimeter and have relatively few rearings. The
idea is that if an animal is hyperactive, they will not only travel farther and more
frequently, but will also have more rearings and center box entries. The SHR is
frequently found to have high measures of locomotion in this test113.
In terms of construct validity, there is support that SHR genetics, behavior, and
neurobiology conform to a theoretical rationale for ADHD. Recently, genetic similarities
have been found between the SHR and those with ADHD. A 160bp insertion was found
in the non-coding region of the DAT1 gene, just as genetic differences in the DAT1 gene
of humans with ADHD have also been reported27,29,114–116. In addition, DAT1 expression
is altered as it has been found to be reduced in SHR midbrain during the first postnatal
month compared to controls, but then is increased after one month117,118. Adult SHR also
have decreased extracellular dopamine levels in the caudate nucleus120,121. In addition,
SHR also exhibit smaller brain volume, such as in the prefrontal cortex and hippocampus,
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than controls, which has also been observed in humans with ADHD122. Furthermore, DA
uptake, storage and metabolism are disturbed in SHR, consistent with one of the primary
propositions for ADHD physiology111,123–125. In animal studies, DA turnover is used as a
reflection of dopamine utilization, with the lower ratio indicating low dopamine
utilization, and possibly hypodopaminergic signaling120,126. Homovanillic acid (dopamine
metabolite) / dopamine ratio has been found to be lower in several brain areas in SHR
versus WKY.
Given the strength of the behavioral similarities of the SHR to ADHD-like
behavior, it is argued that it passes predictive validity105. Many researchers have argued
for altered reinforcement processes as a rationale for ADHD symptoms, and these
processes were discovered via the use of an animal model107,110,127–129. Future studies
utilizing the SHR may help localize neurobiology, genetic, or physiological abnormalities
that underlie the disorder.
One potential confounder with the SHR is the development of hypertension.
Hypertension develops naturally as the SHR reach adulthood, therefore it is advised to
study juvenile, pre-hypertensive rats for ADHD research (before 10-12 weeks of
age)112,130. However, it has been shown that the hyperactive behavior is independent of
hypertensive status131,132.

1.5.3

Animal Intervention Studies

The use of SHR in ADHD studies is becoming increasingly popular. Dervola et
al.133 tested the impact of an omega-3 enriched diet on male and female SHR sustained
attention, impulsiveness, and hyperactivity. The researchers used a dual lever operant
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chamber and a behavioral test as described previously. The male rats on the omega-3 diet
displayed improved attention, decreased hyperactivity and decreased impulsiveness. The
female rats, on the other hand, displayed no change or the opposite effect. One thought is
that the female SHR is not validated as a proper representation of ADHD and thus may
not respond to treatment as expected. Furthermore, the omega-3 diet was much higher in
fat than the control diet. Thus, the higher energy the omega-3 diet provided may have
affected the rats’ behavior, explaining the opposite response of the females. In addition to
behavioral outputs, the authors measured dopamine and serotonin and their respective
degradation products (HVA and 5-HTAA) in order to measure dopamine and serotonin
turnover. Dopamine turnover was improved with the omega-3 diet in the male SHR,
which correlated with the improved changes in behavior. A recent study by Hauser et al.
compared the effects of an omega-3 enriched diet to an omega-3 deficient diet on SHR
hyperactivity using an open field maze. The researchers found that the SHR on the
omega-3 enriched diet were less hyperactive than rats on the deficient diet, further
supporting the importance of omega-3 fatty acids in healthy motor control and
behavior134.

1.6

Oxidative Stress and Attention-Deficit/Hyperactivity Disorder

Given the subgroup of those with ADHD exhibiting secondary omega-3 PUFA
insufficiency, our lab suspected systematic oxidative stress as a contributing factor. There
are several ways to measure oxidative stress. For example, total GSH intracellular
concentration is an indicator of oxidative stress135. GSH is found in two forms, the
reduced GSH form and the oxidized glutathione disulfide form (GSSG). Oxidative stress
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can impact the GSH/GSSG ratio as well as total GSH. GSH can be measured by a wide
variety of high-pressure liquid chromatography (HPLC) methods, which can detect GSH
at picomolar concentrations. However, this process can have poor recovery of GSH135.
Another method is to conduct a recycling kinetic assay, which allows for rapid and
accurate measurements of GSH, GSSG, and GSH + GSSG.
It has been established that a decrease in GSH concentration may be associated
with the pathogenesis of many diseases, such as: AIDS, alcoholic liver disease,
respiratory distress syndrome, and rheumatoid arthritis136. A decrease is also known to be
associated with aging and has been observed in the substantia nigra of Parkinson Disease
patients137,138. A depletion of total GSH (GSH + 2GSSG + protein-bound glutathione)
and a decreased GSH/GSSG ratio are known indicators of oxidative stress in ischemic
brain disease139, cancer140, and cardiovascular disease141. However, GSH concentrations
are increased in the epithelial lining fluid of chronic smokers142.
In 2003 our lab found significant correlations between an increase in red blood cell
(RBC) α-tocopherol concentrations and a decrease in ADHD symptoms. Furthermore,
Ross et al. reported increased exhalation of ethane in subjects with ADHD, a marker of
omega-3 PUFA per oxidation143. Thus, we have suspected systematic increased oxidative
stress as a potential factor in ADHD144. In 2006 we measured glucose-6-phosphate
dehydrogenase activity in red blood cells, a marker of oxidative stress, in young adults
with ADHD from Purdue University. Surprisingly, there was not a significant difference
in activity in the ADHD group versus healthy controls. Furthermore, F2-isoprostane
concentrations measured in urine were not elevated in those with ADHD145. Nonetheless,
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given the current evidence, it is still worth examining this potential factor in animal
models for ADHD.

1.7

Summary and Research Questions

ADHD is a prominent behavioral disorder affecting 5% of children and adults
worldwide6. While medical treatments are available, they only work for up to 70% of the
population and have unwanted side effects146. Thus, alternative treatment options are
frequently investigated. Omega-3 fatty acids continue to be a common topic in ADHD
research. While many research studies support the efficacy of omega-3 supplementation,
continued research is needed to determine the best dosage, delivery method, and identify
whether a subgroup of the ADHD population would benefit more from omega-3
supplementation than others. Furthermore, the impact of omega-3 deficiency or
supplementation on ADHD-symptoms may bring light as to the etiology of the disorder.
Animal models can be used to elucidate the mechanism by which omega-3 fatty acids
elicit their impact on behavior, pending that this effect is consistent.
At present there are only a few studies investigating dietary interventions on
ADHD-like behavior in the SHR. In Chapter 3 we describe our study in which we aim to
address the question of whether an omega-3 dietary intervention will reduce hyperactivity
and modulate neurobiology and biochemistry in the SHR. Our first aim was to evaluate
the impact of an omega-3 enriched diet on ADHD-like behavior. We hypothesized that an
omega-3 enriched diet will reduce hyperactivity in the SHR, as seen in previous studies.
We designed a 2x2 study in which we also tested the validated control strain, WKY, in
order to control for a potential differential impact of the diet, and to record any
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physiological or behavioral differences between strains. In regards to this, our second aim
was to evaluate the impact of diet or strain on neurotransmission, oxidative stress, and
fatty acid proportions in the brain and plasma. We hypothesized that the omega-3
enriched diet would modulate neurotransmission, reduce oxidative stress, and increase
omega-3 polyunsaturated fatty acid proportions in the brain and plasma phospholipids.
We also hypothesized that the SHR will be more hyperactive, have lower dopamine and
serotonin turnover, higher oxidative stress, and lower omega-3 PUFA proportions. In
addition, we conducted a preliminary study on SHR and WKY on standard rat chow to
establish protocols for testing ADHD-like behavior (Chapter 2).
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CHAPTER 2. PILOT STUDY

2.1

Introduction

A pilot study was conducted to confirm a behavioral difference between SHR and
WKY under our testing conditions. SHR and WKY were fed standard rat chow under
food restriction so that they remained around 90th percentile for weight. Sucrose pellets
were used as a reward for lever pressing in a dual lever operant chamber. An open field
maze was utilized to record locomotion as a measure of hyperactivity.

2.2
2.2.1

Methods
Animal Models

The study was approved by Purdue Animal Care and Use Committee (PACUC),
and conducted in concordance with the laws regulating experiments on live animals in
the United States. 8 male, 3-week old Spontaneously Hypertensive Rats (SHR/NCrl) and
8 Wistar Kyoto Rats (WKY/NCrl) were purchased from Charles River International, Inc.
Rats were initially housed 2/cage for 1 week with access to rat chow and water ad
libitum, after which they were housed in individual cages. Rats were handled daily for the
first two weeks and weighed continuously throughout the study. At 4 weeks of age food
was restricted so that rats would be at their 90th percentile for weight. Rats were exposed
to a few sucrose pellets a few days before testing to reduce their novelty. Growth rate and
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body weight were monitored to ensure proper growth, and rats maintained 80% of their
average expected weight. The animals were caged under standard conditions (humidity
about 55%, temperature about 22ºC, reverse 12h light/dark cycle).

2.2.2

Diet

Rats were fed standard rat chow (Nestle Purina Pet Care Company, St. Louis,
MO). Dustless Precision 45mg Sucrose Pellets (Bio-Serv, Flemington, NJ) were used as a
reward during testing. Sucrose pellets were composed of: sucrose, dextrose, cellulose,
tablet binder, magnesium stearate, natural and artificial flavors, calcium silicate, and food
dye (protein 0%, fat 0%, carb 97.5%).

2.2.3

Behavioral Testing

Table 1: Behavioral Training and Testing Schedule
Behavioral Procedure

Number of Sessions

Reinforcement Schedule

Magazine Training

1

Flap Training

2-3

FT 10

Shaping of lever-pressing

4-6

CRF

30 minute training

7-9

FT 10

60 minute training

10-14

VI 15

60 minute Testing
15-34
VI 60
Reinforcement was given either as a continuous reinforcement schedule (CRF), fixed
time of reinforcement (FT), or variable interval schedule of reinforcement (VI)
At 5 weeks of age the 16 animal started the training schedule detailed above
(Table 1). Testing ran daily between 10:00 and 14:00. Rats were randomized to one of
the four chambers, and were tested at the same time each day. The 34 sessions included
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training, lever shaping, and testing with reinforcers. Sessions used in the behavioral
analysis lasted 60 minutes or until 45 pellets were rewarded.
After animals were magazine trained, lever-pressing training began on one lever.
The animals ran on continuous reinforcement and then fixed interval 10s sessions to
strengthen the behavior. For their final schedule, rats were put on a variable interval 60s
(VI60) schedule of reinforcement. Pressing the lever, signaled by a lit cue light above the
lever, produced a reward on a VI60 schedule of reinforcement. While this occurs, the cue
light above the lever turns off and the cue light in the reinforce-delivery hopper turns on.
Following the reinforcer delivery, a VI60 timer is initiated to determine the time until the
cue light turns on again.

2.2.4

Apparatus

The rats were tested in 4 operant chambers (Model 80004NS, Lafayette
Instrument, Lafayette, IN). The chambers were equip with stainless steel floors, fixed
lever press bars requiring a weight of 28mg to activate, and a white, opaque cue light
above each lever. The animals had a working space of 30.5cm L x 26cm D x 20.0cm H.
45mg sucrose reward pellets were dispensed in a small, recessed cubicle with a cue light
that lit when rewards were dispensed. Abet II 2.16 (Lafayette Instruments Abet II,
Lafayette, IN, USA) was used to record behavior and schedule reinforcements and lights.

2.2.5

Measurement of Behavior

The number of presses on the reinforcer-producing lever, time of events, and
number of reinforcers produced and collected were recorded. Attention was calculated as
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a measure of accurate responses on the reinforcer-producing lever as the animal had to
pay attention to the cue light above the lever before pressing. Hyperactivity was
measured as total number of lever-presses in the operant chamber, and distance travelled
and rearings in the open field test133.

2.2.6

Open Field

The open field test was used to measure locomotor activity. The open field
apparatus was a wooden 107cm x 107cm open-field box, with a Plexiglas floor. A 25-box
grid was created with masking tape placed underneath the Plexiglas. Each square was
20cm. Testing was conducted at 10 weeks of age. Rats started at the same corner of the
box each time and allowed to roam uninterrupted for 15 minutes. Two researchers tallied
total box crossings, rearings, and center box entries. Lights were off during testing with
the exception of a red lamp. The maze was cleaned with 70% ethanol and allowed to dry
between sessions. Rats were tested between 11:00-12:00 after their last day in the operant
chamber.

2.2.7

Statistics

SPSS 22 (IBM SPSS Statistics, Armonk, NY) was used to conduct one-way
ANOVA with repeated measures on the operant chamber behavioral outcomes, after data
passed for normality and equal-variance. Kruskal Wallis test was used to determine
normality for all data. Values were considered outliers if they were more than two
standard deviations away from the mean. Student’s t-test was used to evaluate the open
field test outcome measures. Significance was defined as p < 0.05. Values in figures
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reported as mean + standard error of mean (SEM), values in text reported as mean +
SEM.

2.3
2.3.1

Results

Operant Chambers

Figure 5: Mean percent accuracy (correct presses/total presses) for WKY and SHR (mean
+ SEM), n = 8
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Figure 6: Mean total lever presses for WKY and SHR (mean + SEM), n = 8
No statistically significant differences were observed between strains. Mean
percent accuracy was 82.9+2.1 for WKY and 83.2+2.1 for SHR. Mean total lever presses
were 1231.24+200.13 and 1343.26+200.13 for WKY and SHR, respectively. There was,
however, a significant impact of day as both percent accuracy (p = 0.002) and total lever
presses (p = 0.028) increased throughout the study.
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2.3.2

Open Field Maze

Figure 7: Mean box entries, rearings, and center box entries for the open field maze test
for WKY and SHR. x,ySignifies significant difference between strains (p < 0.05). Mean +
SEM, n = 8
SHR had significantly more box crossings (276.38+9.34 vs 90.38+18.52), rearings
(92.25+4.51 vs 18.25+3.02) and center box entries (7.38+0.86 vs 0) than WKY
(p < 0.001).

2.4

Discussion and Conclusion

Rats were only at 80th percentile of their expected growth, which is lower than the
target 85-90th percentile desired. While an increase in diet was enlisted to promote further
weight gain, the intervention was not strong enough. Consequently, the animals could
have been more motivated than usual because of the increased need for food. While a
behavioral strain difference has been observed in multiple studies112, our single-lever
operant chamber tests did not reveal a difference in behavior between the two strains.
However, the open field maze did show a significant strain effect. Thus, we chose to
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focus on hyperactivity and proceed with the open field maze test for our subsequent study.
Our data suggests that a dual-lever discrimination test may be needed to reveal the
behavioral differences observed in other studies.
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CHAPTER 3. INTERVENTION STUDY

3.1

Introduction

Attention-deficit/hyperactivity disorder is the most commonly diagnosed
behavioral disorder in children worldwide. Diagnosis rates have been increasing steadily
in the United States, with up to 11% of children diagnosed with the disorder as of 20116.
ADHD is diagnosed based on symptoms detailed in the DSM-V, which include:
inattention, hyperactivity, and impulsivity1. Dopamine abnormalities have been heavily
implicated in the physiology of ADHD30. Multiple studies have confirmed a low
dopamine response, lower dopamine receptor availability, and smaller brain region
volumes in areas known to be rich in dopamine receptors10,29,147,148. Stimulant
medications that prevent dopamine reuptake or increase dopamine release are effective
for treating symptoms, but these medications only work for around 70% of the
population146.
The complete etiology of ADHD remains unknown, but clear environmental and
genetic factors have been identified31,149. Nutritional insufficiencies, particularly essential
fatty acids, have been a topic of interest in ADHD research. Essential polyunsaturated
fatty acids such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are
crucial for healthy brain development. EPA and DHA, or their precursor alpha-linolenic
acid (ALA), must be obtained from the diet as the body cannot synthesize them otherwise.
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Most brain development occurs prenatally and during the first few years of life,
therefore having adequate omega-3 PUFA is particularly important during this time150,151.
The typical Western Diet consists of a very high omega-6 fatty acid: omega-3 fatty acid
ratio (15:1) as opposed to the recommended ratio of 4:152,53,152. Our lab has investigated
essential fatty acid (EFA) status in children with ADHD, as many displayed EFA
deficiency symptoms (i.e. increased thirst, dandruff, frequent urination). We found that a
subgroup of children with ADHD, about 40%, had insufficient plasma EFA levels despite
reporting a similar diet to the other children tested44,153. This finding has been
subsequently reported by other labs as well, both within and outside the United States45,46.
Furthermore, feeding infants baby formula, which lacked added essential omega-3 PUFA
until 2002, is significantly correlated with increased ADHD risk47. Consequently, omega3 PUFAs have been implicated as a possible environmental factor in ADHD risk and
development.
The importance of adequate omega-3 PUFAs for healthy brain physiology has been
demonstrated in several neurobiology and behavior studies on omega-3 PUFA deficient
animals. Omega-3 PUFA deficiency, especially during times of heightened brain
development, can have detrimental effects on learning, brain structure and function151.
EPA and DHA are crucial for membrane fluidity, proper neurotransmission, and brain
development154. Animal studies evaluating the impact of animals on an omega-3 deficient
diet for multiple generations report decreased performance on learning and memory tasks,
lower dopamine and serotonin concentration, and lower dopamine storage69,81,83,94,155,156.
Interestingly, both learning and neurotransmitter deficits have been successfully reversed
with omega-3 PUFA supplementation92,157. Omega-3 supplementation has been evaluated
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for its impact on ADHD and several human and animal studies have reported a reduction
in ADHD-symptoms. The results of these intervention studies, however, have not been
unanimous158.
In order to eliminate the risk of “placebo effect” and evaluate more invasive
physiological factors, we utilized the Spontaneously Hypertensive Rat (SHR). The SHR
is a well-validated animal model for ADHD, and displays all three major behavioral
characteristics of the disorder105,112,159. In our study, we examine the impact of an omega3 enriched diet (2:1 omega-6:omega-3 ratio) versus a typical Western Diet (13.3:1) on
hyperactivity, a common ADHD behavior. Juvenile SHR and their validated control
strain, Wistar Kyota Rat (WKY), were fed either an omega-3 fatty acid dominant diet
(omega-3 diet) or an omega-6 fatty acid dominant diet (omega-6 diet) followed by
locomotion and rearing measurement in an open field maze. Dopamine abnormalities are
heavily implicated in ADHD behavior, so we measured DA and its downstream
neurotransmitter, serotonin (5-HT), turnover in the neostriatum. Additionally, both
plasma and brain phospholipid compositions were assessed. Lastly, as oxidative stress
could be a causative factor in secondary omega-3 PUFA deficiency, we analyzed liver
glutathione (GSH) concentrations as a measure of oxidative stress. We hypothesize that
the omega-3 diet will increase omega-3 PUFA proportions in plasma and brain
phospholipids, increase DA and 5-HT turnover, and reduce oxidative stress, which will
be correlated with a decrease in hyperactivity. We also hypothesize that the SHR will be
more hyperactive, have lower neurotransmitter turnover, and a higher state of oxidative
stress than the WKY.
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3.2

Materials and Methods

3.2.1

Animal Models

The study was approved by Purdue Animal Care and Use Committee (PACUC),
and conducted in concordance with the laws regulating experiments on live animals in
the United States. 16 male, 3-week old Spontaneously Hypertensive Rats (SHR/NCrl)
and 17 Wistar Kyoto Rats (WKY/NCrl) were purchased from Charles River International,
Inc. Rats were initially housed four/cage for four days with access to standard rat chow
and water ad libitum, after which they were randomized into two diet groups: omega-3
enriched diet or omega-6 dominant diet. The extra WKY was placed in the omega-3 diet
group. After one week rats were switched to individual cages. Rats were handled daily for
the first two weeks and weighed continuously (every 3 days) throughout the study. Both
groups had ad libitum access to their specified food and water. Food intake was
calculated daily to ensure similar intake between groups. Growth rate and body weight
increased as expected, and there was no difference in weight gain between dietary groups.
The animals were caged under standard conditions (humidity about 55%, temperature
about 22ºC, reverse 12h light/dark cycle).
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3.2.2

Diet

Table 2: Dietary Composition of the Omega-3 and Omega-6 Diets
Modifications

Omega-3 Diet

Omega-6 Diet

Soybean Oil

35g/kg

35g/kg

Menhaden Oil

36g/kg

-

Corn Oil

-

36g/kg

α-tocopherol

133.5 IU/kg

133.5 IU/kg

Table 3: Fatty Acid Composition of Both Diets (% Proportion)
Fatty Acids

Omega-3 Diet

Omega-6 Diet

16:0

16.96

12.60

18:0

6.27

0.13

16:1n7

4.19

3.12

18:1n9c

16.15

26.34

18:1n9t

2.58

0.94

18:2n6c (LA)

33.23

56.08

18:3n6

0.83

0.59

18:3n3

4.87

0.19

20:3n6 (DGLA)

0.03

-

20:4n6 (AA)

0.62

-

20:5n3(EPA)

7.36

-

22:6n3 (DHA)

6.90

-

Diets were modified from Bio-Serv AIN-93G standard rodent diet
(http://www.bio-serv.com/Rodent_Standard_Diets/RDAIN93G.html). Solely the fat
content was modified to ensure equivalence between diets with exception to fatty acid
composition. The composition of both diets was as follows: 59.3% carbohydrate, 18.1%
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protein, 7.1% fat, 4.8% fiber. The omega-3 enriched diet contained menhaden oil, while
the omega-6 diet contained an equivalent amount of corn oil. Both diets had an
equivalent amount of soybean oil. Consequently, the omega-3 enriched diet contained
omega-3 long chain polyunsaturated fatty acid (LC-PUFA) EPA and DHA whereas the
omega-6 diet had high amounts of omega-6 LC-PUFA precursor linoleic acid (LA) but no
omega-3 LC-PUFAs. Furthermore, the omega-3 enriched diet had an omega-6:omega-3
ratio of 2:1, whereas the omega-6 diet had a ratio of 13.3:1. α-tocopherol was added to
both diets to protect against lipid peroxidation. See Table 2 and 3 for detailed
composition information.

3.2.3

Behavioral Experiment

The open field test was used to measure locomotor activity. The open field
apparatus was a wooden 107cm x 107cm open-field box, with a Plexiglas floor. A 25-box
grid was created with masking tape placed underneath the Plexiglas. Each square was
20.3cm. Testing was conducted at 8 weeks of age. Rats started at the same corner of the
box each time and allowed to roam uninterrupted for 15 minutes. Two researchers tallied
total box crossings and rearings. Lights were off during testing with the exception of a
red lamp. All testing sessions were recorded by a camcorder and reevaluated by
researchers. The maze was cleaned with 70% ethanol and allowed to dry between
sessions. Rats were tested between 10:00-13:00 six days a week. Each rat was tested at
the same time every other day, for a total of three trials.
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3.2.4

Euthanasia

Rats were euthanized at 10 weeks of age via CO2 exposure and cardiac stick.
Blood was collected via cardiac stick and stored in EDTA tubes (EDTA used as an
antiocoagulant). Tubes of blood were mixed on a rocking mixer and then stored on ice
until final storage in freezer. Kidney, liver, brain, and spleen were collected, wrapped in
foil, and immediately frozen in liquid nitrogen. The neostriatum was separated from the
rest of the brain and also frozen.

3.2.5

Analysis

Blood was centrifuged for 20 minutes at 3000g. Plasma was collected and
aliquoted for storage in -80ºC. Liver, brain, spleen, and kidney were also washed and
stored in -80ºC until analysis.

3.2.5.1 Phospholipid and Oxidative Stress Analysis
Chemicals and Materials: Methanol and chloroform were purchased from Macron
Fine Chemicals (Central Valley, PA). Solid phase extraction (SPE) silica cartridges
(500mg, 6ml) and holder were purchased from Burdick & Jackson (Muskegon, MI).
Bovine serum albumin (BSA) protein assay kit and dye reagent concentrate were
purchased from Bio-Rad Laboratories, Inc. (Hercules, CA). 96 Well Tissue Culture Plates
(flat bottom) and 15ml polypropylene conical tubes were purchased from Falcon
(Corning Science Mexico S.A. de C.V.). All other chemicals and reagents were purchased
from Sigma-Aldrich (St. Louis, MO).
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3.2.5.1.1 Phospholipid Composition Method
Plasma: 0.5ml of plasma was thawed and added to a medium test tube. 3.5ml of
methanol was added to the plasma followed by 7ml of chloroform. The solution was
filtered through Whatman #5 paper then washed with 6ml chloroform:methanol. 3ml
0.88% KCL was added and the solution was vortexed for 2 minutes. Samples were then
refrigerated overnight. The bottom chloroform layer was removed and dried under
nitrogen in a 37ºC water bath. Afterwards samples underwent column separation via solid
phase extraction silica cartridges. Cartridges were washed with 10ml of chloroform then
dried plasma lipids were dissolved in 0.5ml of chloroform and poured through the
column. Once the lipid solution was absorbed, another 10ml of chloroform was added to
the cartridge, followed by 10ml of methanol. The fraction was collected and then an
additional 10ml of methanol was added. The columns were then washed with 20ml
methanol and 20ml of chloroform. Methanol fractions were combined and dried under
nitrogen. Then 1ml of methanol with butylated hydroxytoluene (BHT) and 1ml 14%
boron trifluoride (BF3) were added and the solution was vortexed. Afterwards the test
tube was capped tightly and heated in a 100ºC heating block for 30 minutes. Once cooled,
1ml hexane with butylated hydroxytoluene and 3ml of double-dionized water (DDI) were
added. After vortexing, the top layer was used for gas chromatography (GC) analysis.
Protocol adapted from Juaneda and Rocquelin and Ohta et al.160,161.
Whole brain: Around 0.120g whole brain was cut, weighed and homogenized in
homogenizing buffer (50mM tris-HCl, pH 7.4, 2mM EDTA) to make a 10%
weight/volume (w/v) solution. Phospholipid extraction was conducted as described above
with the exception of the column separation, which was not needed.
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3.2.5.1.2 Oxidative Stress Method
Liver total glutathione (GSH) was analyzed as a marker of oxidative stress, using
a protocol adapted from Rahman et al.135. A section of liver tissue was cut and weighed,
ranging from 0.100g-0.250g in mass. The tissue was then homogenized using a mortar
attached to a Sears Craften drill in enough ice-cold 5% metaphosphoric acid to make a
20% w/v solution. The samples were then centrifuged at 3000g for 20 minutes at 4ºC in
15ml conical vials. Reagent buffers were made fresh according to instructions with the
exception of DTNB and β-NADPH solution. DTNB solution was made using 4mg of
Elmands reagent, and β-NADPH was made using 6mg β-NADPH. GSH standards ranged
from 3.13µg/ml – 50µg/ml. For the spectrometer analysis, 25µL of sample or standard
was loaded into each well of the 96-well plate, followed by 115µL of the GR/DTNB
mixture. After 90 seconds, 60µL of β-NADPH was added. The plate was immediately
read via spectrometer (PowerWave Bio-Tek Instruments, Inc. Winooski, VT) and GSH
concentration was calculated using a standard curve. GSH concentration was then
normalized to protein for statistical analysis.

3.2.5.1.3 Protein Assay
A 1:10 dilution of Bio-Rad protein assay dye reagent concentrate and bovine
serum albumin were used for the protein assay. BSA standard concentrations ranged from
0.0625mg to 0.50mg. 5µl of DDI water, standard, or sample was pipetted into a 96-well
plate. 200µl of dye was added to each well. Plate was immediately analyzed at 595nm via
spectrometer.
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3.2.5.2 Neurotransmitter Analysis
3.2.5.2.1 Chemicals
A high performance liquid chromatogrpahy (HPLC) machine was utilized to
conduct monoamine analysis. Dopamine, homovanillic acid, and serotonin standards
were obtained from Arcos Organics, while 5-hydroxyindole-3-acetic acid (5-HIAA) and
isoproterenol were obtained from Sigma.

3.2.5.2.2 Sample Preparation
Neostriatum samples were weighed and homogenized in 500uL of ice-cold 0.2M
HCLO4. The homogenizer was the same mortar and pestle mounted to a Sears Craften
drill used for the previous tissue sample analyses. The suspension was mixed with ISO (a
monoamine internal standard) in 0.12mM ascorbic acid, bringing the final concentration
to 500µM ISO. The homogenates were centrifuged at 12,0000g at 2ºC for 30 minutes.
Supernatents were stored at -20ºC until analysis. Samples were filtered through 0.22µm
nylon syringe filters into glass vials for HPLC analysis.

3.2.5.2.3 Monoamine Analysis
Reverse-phased HPLC (ESA), equipped with a phenomenex Kinetex 2.6µM C18
column (inner diameter 4.6mm, length 100mm) was used for monoamine analysis. ESA
CoulArray electrochemical detectors had working potentials 200, 225, 250, 275, 325,
350, and 375mV. The mobile phase consisted of 20mM sodium phosphate buffer, pH 2.5,
and 1% methanol in a 1:1 solution of the 20mM sodium phosphate buffer, pH 2.5, and
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100% methanol. Mobile phase was varied on a gradient so that the methanol percentage
ranged from 1%-25%. Individual samples were eluted at 35 minutes with a flow rate of
0.7mL/min. Known concentrations of external standards were analyzed on the same day.
Chromatograms were analyzed using ESA CoulArray and monoamine concentrations
were expressed in pmol/mg protein.

3.2.6

Statistical Analysis

Behavioral outcomes were analyzed using two-way ANOVA with repeated
measures on SPSS 22. GSH, neurotransmitter, and phospholipid comparisons were
analyzed using two-way ANOVA, passing tests for normality and equal variance on
SigmaStat (Jandel Scientific Software, San Jose, CA) or SPSS 22 (IBM SPSS Statistics,
Armonk, NY). Kruskal Wallis test was used to determine normality for all data. Outliers
were considered any value greater or less than two standard deviations. Variables for all
ANOVA tests were strain and diet. Data that did not pass normality were transformed
using either 1/x2 or 1/x transformation. Student t-test was used to analyze plasma EPA
data as only the omega-3 diet group had non-zero values. For all tests p < 0.05
established significance. One-way ANOVA was run using SPSS 22 if there was a strain x
diet interaction.
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3.3
3.3.1

Results

Behavioral Analysis

The results of the open field maze test for hyperactivity are graphed below.

Figure 8: Mean total box entries spanning the three trial days of WKY and SHR for both
diets, n = 7-9. x,ySignify significant difference between strains, d,e,fsignify significant
impact of day. Values are mean + SEM.
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Figure 9: Mean total rearings spanning the three trial days of WKY and SHR for both
diets, n = 7-9. x,ySignify significant differences between strains, a,bsignify significant
impact of diet. Values are mean + SEM.
Total box crossings and rearings were analyzed with two-way ANOVA with
repeated measures (Figures 8 and 9). No effect of diet was found for total box crossings
or rearings. However, there was a significant difference among strains for both measures
(p = 0.003 box crosses, p = 0.000 rearings). SHR crossed a mean of 244.98+11.96 boxes
and averaged 101.52+3.65 rearings over the three testing days. WKY scored significantly
less than the SHR, with an average of 166.72+11.62 box crossings and 32.11+3.31
rearings. For the WKY, the average box crossings were impacted by day (p = 0.024),
while average box crossings for SHR did not change significantly. WKY stuck to the
perimeter of the maze or rested in one corner, while the SHR moved quickly and
frequently across the entire maze.
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3.3.2

Plasma and Brain Phospholipid Composition

Data for plasma and brain fatty acid proportions are presented in tables 4 and 5, while the
three main omega-6 and omega-3 LC-PUFAs are graphed (Figures 10 and 11).

Table 4: Fatty acid composition of the plasma of WKY and SHR on both diets (%
proportion)
Plasma Phospholipids
Fatty Acids

WKY
Omega-6

SHR
Omega-3

Omega-6

Omega-3

16:0

23.41+0.60

a

26.88+0.60

b

25.23+0.63

a

26.76+0.60b

18:0

27.46+1.60

24.45+1.60

29.40+1.67

27.98+1.60

16:1n7

0.59+0.10a,x

0.95+0.10b,x

0.27+0.10a,y

0.83+0.10b,y

18:1n9c

6.93+0.40a

8.10+0.40b

6.83+0.50a

7.91+0.40b

18:1n9t

2.90+0.20x

3.01+0.20x

2.21+0.20y

2.68+0.20y

18:2n6c (LA)

10.54+0.80a

13.05+0.80b

10.72+0.90a

13.25+0.80b

20:3n6 (DGLA)

0.19+0.10a

0.83+0.10b

0.07+0.10a

0.77+0.10b

20:4n6 (AA)

25.39+0.80a,x

13.05+0.80b,x

21.96+0.80a,y

11.61+0.80b,y

20:5n3(EPA)

0.04+0.28a,x

3.55+0.28b,x

0+0.28a,y

1.58+0.28b,y

22:6n3 (DHA)
2.50+0.27a,x
5.56+0.27b,x
3.31+0.29a,y
a,b
Different letters signify significant difference between diets
x,y
Different letters signify significant difference between strains
All values are means+SEM, n = 6-8

6.36+0.27b,y
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Figure 10: A. Mean plasma phospholipid proportion of arachidonic acid (AA), B.
eicosapentaenoic acid (EPA), C. and docosahexaenoic acid (DHA) in the WKY and SHR
for both diets, n = 6-8.x,ySignify significant differences between strains, a,bsignify
significant impact of diet. Mean + SEM.
Table 5: Fatty acid composition of brain in WKY and SHR on both diets (% proportion)
Phospholipids
Fatty Acids

WKY

SHR

Omega-6

Omega-3

Omega-6

Omega-3

16:0

23.51+0.30a,x

22.30+0.28b,x

24.20+0.30a,y

23.67+0.30b,y

18:0

22.79+0.36

23.53+0.34

22.99+0.36

23.36+0.36

16:1n7

0.51+0.02a

0.61+0.02b

0.51+0.02a

0.67+0.02b

18:1n9c

19.24+0.39a,x

20.71+0.37b,x

18.64+0.39a,y

19.15+0.37b,y

18:1n9t

4.48+0.09x

4.41+0.08x

4.07+0.09y

3.92+0.09y

18:2n6c (LA)

1.01

0.98

1.04

0.97

20:4n6 (AA)

12.54+0.20a

10.23+0.20b

12.06+0.20a

10.57+0.20b

20:5n3(EPA)

0.36+0.02x

0.37+0.02x

0.31+0.02y

0.28+0.02y

22:6n3 (DHA)

15.58+0.36a

16.86+0.36b

16.13+0.36a

17.33+0.36b

AA/DHA
0.80+0.02a
0.61+0.02b
0.75+0.02a
a,b
Different letters signify significant difference between diets
x,y
Different letters signify significant difference between strains
All values are mean+SEM, n = 8-9

0.61+0.02b
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Figure 11: A. Mean brain phospholipid proportion of arachidonic acid (AA), B.
eicosapentaenoic acid (EPA), C. and docosahexaenoic acid (DHA) in the WKY and SHR
for both diets, n = 8-9.x,ySignify significant differences between strains, a,bsignify
significant impact of diet. Mean + SEM.
Table 4 and 5 summarize the fatty acid composition of plasma and whole brain
phospholipids for SHR and WKY on both diets. The omega-3 enriched diet was
successful in significantly increasing DHA in both the brain and plasma, but EPA was
only significantly greater in plasma. Omega-6 PUFA precursor linoleic acid (LA) was
significantly higher with the omega-3 enriched diet in plasma, but arachidonic acid was
significantly lower in both plasma and brain. Interestingly, there was a significant strain
difference for brain EPA and both brain and plasma EPA and DHA, with EPA higher in
the WKY strain and DHA higher in the SHR. AA/DHA ratio in the brain was
significantly lower in rats on the omega-3 diet.
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3.3.3

Total Glutathione

Figure 12: GSH concentration (µg/mg protein) in the liver in SHR and WKY on both
diets. x,ySignify significant differences between strains, a,bsignify significant impact of
diet. Mean + SEM, n = 8-9.
Liver total GSH concentration (µg/mg protein) was significantly impacted by diet, and
differed according to strain. SHR and WKY on the omega-3 enriched diet both displayed
higher GSH concentrations, increasing from 4.63 to 5.37 and 3.54 to 4.52, respectively.
SHR also had significantly higher liver GSH concentration than WKY, independent of
diet. There was not a significant strain x diet interaction (Figure 12).

59
3.3.4

Neurotransmitters

Figure 13: A. Dopamine (DA) concentration, B. homovanillic acid (HVA) concentration,
and C. dopamine turnover (HVA/DA) in the neostriatum of SHR and WKY on both diets,
n = 6-8. x,ySignify significant differences between strains, a,bsignify significant impact of
diet. Mean + SEM.

Figure 14: A. Serotonin (5-HT) concentration, B. 5-hydroxyindole-3-acetic acid (5HIAA) concentration, and C. serotonin turnover (5-HTAA/5-HT) in SHR and WKY
neostriatum on both diets, n = 6-8. x,ySignify significant differences between strains,
a,b
signify significant impact of diet. Mean + SEM.
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DA, HVA, 5-HT, and 5-HTAA were measured using HPLC and normalized to internal
standard (pmol/mg). DA concentration differed significantly between strains, with WKY
having lower neostriatal DA concentration on both diets (17.18+1.41 SHR vs 12.48+1.36
WKY, p = 0.023). DA concentration was lower in SHR with the n-3 enriched diet, and
this difference was found to be significant using one-way ANOVA. There was also a
significant diet x strain interaction (p=0.047) (figure 13). There was not a significant
impact of strain or diet on HVA concentration. Interestingly, SHR had significantly lower
dopamine turnover than WKY on both diets (0.053+0.002 SHR vs. 0.071+0.002 WKY, p
= 0.000). Serotonin concentration was significantly lower with the n-3 enriched diet for
both strains (0.463+0.043 vs. 0.328+0.041 omega-6 vs omega-3 WKY and 0.533+0.043
vs. 0.430+0.046 omega-6 vs omega-3 SHR, p = 0.011) but there was no strain difference
or strain x diet interaction. The diet did not have an impact on the serotonin degradation
product, 5-HTAA, but there was a significant strain difference with WKY having a lower
concentration of 5-HIAA than SHR (0.536+0.045 WKY vs. 0.671+0.048 SHR, p = 0.049)
(Figure 14). Despite these differences there was no between strain, diet, or strain x diet
interaction on serotonin turnover.

3.4

Discussion

The current 2 x 2 design study provides insight into the impact of an omega-3
enriched diet on the behavior and biochemistry of the SHR. To the authors’ knowledge, it
is also one of few studies that compare an omega-3 enriched diet to a diet typical of a
western diet – a more realistic scenario than comparing to an omega-3 deficient diet. The
SHR and WKY received a diet with either a 2:1 or 13.3:1 ratio of omega-6:omega-3 fatty
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acids. Our goal was to test if altering the omega-6:omega-3 ratio would be enough to
impact behavior and neurobiology. Thus, the diets only differed in their fat source and
fatty acid ratio. We found that the omega-3 diet was successful in changing phospholipid
proportions and altering a marker of oxidative stress in both strains but not in modulating
behavior or neurotransmission. We also further confirmed both biochemical and
behavioral strain differences between the SHR and WKY, including inherent differences
in plasma and brain phospholipid composition, neurotransmission and oxidative stress
markers.
Rats in both dietary groups remained healthy and grew as expected throughout the
study, with no differences between groups. As predicted, the SHR was significantly more
hyperactive than the WKY. However, our dietary intervention had no impact on behavior
in either strain. That being said, the lack of impact on behavior is consistent with our
neurotransmitter results.
The omega-3 diet was successful in improving omega-3 PUFA proportion in both
plasma and brain phospholipids. Of particular interest, strain differences were observed
in plasma AA, EPA, and DHA. Unexpectedly, SHR had higher plasma DHA than WKY
while WKY had higher plasma and brain EPA. The dietary intervention was effective in
changing overall plasma and brain phospholipid composition, with the exception of EPA
in the brain. This differs from our observations in previous human studies, where a
subgroup of children and adults with ADHD had low proportions of plasma phospholipid
DHA. A recent study on SHR and hyperactivity also reported higher DHA proportion in
the brain compared to WKY. The researchers investigated the correlation between
AA/DHA ratio and hyperactive behavior, and found that a higher AA/DHA ratio in the
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brain was significantly correlated with greater hyperactivity. Thus, altering AA/DHA
ratio could have a greater impact on hyperactivity than changing DHA alone154. In our
study, the omega-3 enriched diet was successful in lowering the AA/DHA ratio in brain,
but this did not translate into a change in behavior.
Disturbances in the dopaminergic system can lead to ADHD-like behavior such as
lack of attention, impulsivity, and hyperactivity and are thus thought to be associated
with ADHD. However, focusing on dopamine alone may be an oversimplification of the
disorder, as successful stimulant treatments can also block other monoamine
transporters162,163 and subsequently increase concentrations of DA, norepinephrine (NE),
and 5-HT164,165. That is why we evaluated serotonin turnover in addition to dopamine
turnover. Dopamine concentration was lower for SHR on the omega-3 diet, while
serotonin concentration was lower for both strains. Nonetheless, as no impact was found
on serotonin or dopamine turnover, it can be concluded that our intervention did not have
an overall impact on dopamine and serotonin utilization. However, of note is that the
SHR had lower DA turnover than the WKY, which is consistent with other studies on DA
turnover in SHR126,133. In an omega-3 dietary intervention study conducted by Dervola et
al.133 DA turnover did not differ between SHR on the control diet and WKY, which
differed from our results. On the other hand, their intervention was successful in
improving DA turnover. A noteworthy difference between our studies is the length and
strength of intervention. Dervola et al. supplemented rats with a high dose of omega-3
fatty acids for two generations, which was successful in improving behavior and
modulating neurotransmission133. We chose to focus on juvenile SHR in order to narrow
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down the most effective time period for intervention. We also maintained consistent fat
proportion for both diets to eliminate extra calories as a confounding factor.
Previous studies have provided evidence supporting that those with ADHD may
have increased oxidative stress143,144. There are also multiple papers demonstrating that
adult SHR have higher oxidative stress than their WKY counterparts166,167. Thus, we
hypothesized that we also would find evidence of higher oxidative stress in the SHR than
the WKY. We used GSH as a marker of oxidative stress, with higher concentration
indicative of an improved redox balance and less oxidative stress while very high
concentrations could be indicative of increased oxidative stress. Surprisingly, the WKY
had lower GSH concentration. However, oxidative stress is best understood by evaluating
multiple markers. A secondary oxidative stress marker, such as F2-isoprostanes or
oxidized glutathione (GSSG), will be measured in the future as an internal standard.
Nonetheless, our preliminary data hints that the omega-3 diet was effective in reducing
oxidative stress.
While there was a marked behavioral difference between the SHR and WKY, our
dietary intervention did not have our desired impact on hyperactive behavior. These
results are not surprising, however, given that dopamine neurotransmission was also not
affected. While brain DHA proportion was increased, the dosage or length of time for the
intervention was apparently not enough to have an impact on dopamine or serotonin
turnover. There are few other studies that have tested an omega-3 intervention on SHR
behavior. One such study compared SHR on an omega-3 adequate or omega-3 deficient
diet, and found that the omega-3-adequate diet resulted in less locomotion/hyperactivity
than the deficient diet. However, many studies have already confirmed the detrimental
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impact of omega-3 deficiency on behavior, independent of ADHD status. A very recent
study was published that also looked at an omega-3 enriched diet in comparison to a
primarily omega-6 diet and similarly did not observe a change in hyperactive behavior168.
Studies with our timeline are important because they narrow down the timeframe and
dosage for efficacy of an omega-3 intervention. As a dietary intervention during prenatal
and postnatal growth was successful133, whereas studies during 3-10 weeks of age were
not168, a pre-weaning age range should be investigated in the future.

3.5

Conclusion

In summary, our omega-3 PUFA enriched diet did not improve hyperactive
behavior, consistent with the lack of impact on DA and 5-HT turnover. However, our
intervention successfully increased omega-3 PUFA proportion in plasma and brain, and
may have improved redox balance and decreased oxidative stress in both strains. Further
studies should be conducted investigating the impact of an omega-3 intervention preweaning. Additionally, our study further highlights the inherent behavioral and
biochemical differences between SHR and WKY.
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CHAPTER 4. CONCLUSIONS AND FUTURE DIRECTIONS

ADHD is a multifactorial disorder with conflicting evidence pertaining to its etiology.
Over 11% of children in the United States, and around 5% of both children and adults
worldwide, are affected6. The symptoms of the disorder can negatively impact school
performance, personal relationships, and can lead to greater risk taking behaviors.
Medicinal treatment is effective for around 70% of those with ADHD, but it comes with
the risk of side effects such as decreased appetite and insomnia. Clearly, these side effects
could have unfavorable effects on both children and adults. Consequently, alternative
treatments with fewer side effects are of great interest.
Although the origin of ADHD is not fully understood, what we do know can help
elucidate potential treatments. Our lab has identified a subgroup of children with ADHD
that display essential fatty acid (EFA) deficiency symptoms such as increased thirst,
frequent urination, and dandruff. Subsequently a number of studies, ours included,
reported that as high as 40% of subjects with ADHD had lower proportions of plasma
docosahexaenoic acid than healthy controls and others with ADHD. Omega-3
polyunsaturated fatty acids, EPA and DHA especially, are known to be vital for healthy
brain development and function. In fact, an omega-3 PUFA deficiency can induce
ADHD-like behavior in otherwise healthy animals. In cases of omega-3 PUFA induced
learning deficits and hyperactivity, postnatal omega-3 PUFA supplementation was
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effective in reversing the effects. The reason why DHA proportions are lower in a
subgroup of those with ADHD, despite similar diets to healthy controls, is currently
unknown. However, oxidative stress could be a potential factor, since long chain PUFAs
are easily oxidized. There exists some evidence of increased oxidative stress in those with
ADHD143, and the animal model for ADHD is known to have heightened states of
oxidative stress166,167.
In our study we investigated the hypothesis that an omega-3 PUFA enriched diet
would decrease hyperactivity, modulate neurotransmission, decrease oxidative stress, and
increase omega-3 PUFA proportions in the brain and plasma. One concern was that our
intervention may not have been long enough to modulate brain phospholipid proportions,
but we were successful in increasing DHA proportion, and decreasing arachidonic acid
proportion, in brain. Both EPA and DHA proportions were increased in the plasma. For
the most part, the impact of the omega-3 diet was similar for plasma and brain. However,
some strain differences were only seen in plasma. As reported in a previous study, DHA
proportion in the brain was higher in the SHR than the WKY154. These results went
against our predication that the SHR would also display lower DHA proportions, as seen
in our previous human studies.
Another surprising result was that the SHR seem to have less incidence of oxidative
stress than the WKY based on liver total glutathione concentrations. There is a possible
explanation for this occurrence, however, as GSH alone is not enough to evaluate redox
balance and oxidative stress. In the future, we plan to analyze oxidized glutathione
(GSSG) for a more complete picture of redox balance. F2-isoprostanes can be analyzed as
well as an internal standard. Together, these analyses will provide more reliable
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information on the redox state of the animals. Nonetheless, the omega-3 diet slightly
improved GSH levels, suggesting decreased oxidative stress, which is consistent with the
reports of other studies169. In addition, our diets contained greater vitamin E than in a
typical rodent diet. The increased antioxidant content in the diet could also be a potential
confound to the oxidative stress data, although it was the same for both diets.
Despite the increase in brain DHA proportion, dopamine (DA) and serotonin (5-HT)
neurotransmission was not modulated. DA and 5-HT turnover were similar for both diets,
but DA turnover was lower in the SHR. This is consistent with other studies on the
SHR111,123,124,133, and also consistent with the validation for its use as a model for
ADHD105 .
While our intervention did not elicit a behavioral or neurotransmitter change, it
has provided information on the best time for dietary interventions. As a previous omega3 intervention animal study has been successful in reducing ADHD symptoms, it seems
that the greatest impact occurs pre-weaning or prenatally via maternal supplementation.
In the future it would be beneficial to test the impact of supplementation during isolated
developmental periods, such as solely maternal and prenatal intervention.
Our pilot study discussed in Chapter 2 was done in order to develop behavioral testing
protocols that elucidated the difference in behavior between the SHR and WKY. Our
single-lever operant test was not difficult enough to show any differences between strains.
Other studies have confirmed a behavioral difference when using nose-poke tests or a
dual-lever discrimination task105,133,170. Future studies should utilize these operant
chamber tests when evaluating the impact of treatments or interventions on ADHD-like
behavior in an animal model. On the other hand, the open field maze test was appropriate
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for identifying hyperactivity in the SHR and the number of box crossings and rearings
was significantly higher than for the WKY. Thus, we chose to open field maze test in our
main study.
There is still much to understand in regards to ADHD treatment, etiology, and
neurobiology. As there exists a subgroup of those with ADHD who display EFA
deficiency symptoms, human intervention studies should evaluate that subgroup
separately from the rest. The disparity between the results of human intervention trials
could be due to omega-3 interventions impacting those with low omega-3 PUFA
proportions more so than others. In terms of animal studies, future research should
narrow the age-range for when intervention is most effective. It would also be beneficial
to test high doses of omega-3 EPA or DHA supplementation, such as what is used in
human studies. Furthermore, if it established that an increase in omega-3 PUFA
proportions modulates dopamine neurotransmission in the SHR, research should focus on
which part of the dopaminergic pathway is being affected. Specifically, more research
should be done on dopamine active transporter (DAT) availability and activity, and if
omega-3 fatty acids have an impact. Finally, oxidative stress should continue to be
investigated in the subgroup of those with ADHD who display EFA deficiency symptoms,
as a possible rationale for the lower omega-3 PUFA proportions.
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